London · Delayed Price · Currency is GBP · Price in GBX CelLBxHealth Earnings Call Transcripts
Fiscal Year 2025
-
Revenues declined in 2025 due to slower commercial conversion, but major restructuring and new partnerships have positioned the company for a 50% revenue increase in 2026 and EBITDA breakeven by late 2028. Cash burn is significantly reduced, and the business is funded through Q2 2027.
-
A new leadership team is driving a focused commercialization strategy, restructuring operations, and targeting profitability by 2028. Strategic partnerships and a narrowed market focus aim to capitalize on the growing need for circulating tumor cell diagnostics, with significant cost reductions and value inflection points expected in the next 12-18 months.
-
Major commercialization progress with pharma and medtech, including a new Myriad Genetics partnership, was offset by revenue declines due to market headwinds. Cost controls reduced losses, and the cash runway extends into Q1 2026. NHS engagement and new clinical evidence support future growth.
-
A novel blood-based technology enables real-time, comprehensive cancer profiling by isolating living tumor cells, supporting early diagnosis, treatment selection, and remission monitoring. Strategic pharma partnerships and high-margin product and service revenues position the company for significant growth.
Fiscal Year 2024
-
2024 saw 31% revenue growth, major pharma contracts, and a breakthrough in DNA dual analysis, despite market headwinds and funding delays. The pipeline is strong, with new medtech and pharma opportunities, and a cash runway into Q1 2026.
-
Strong H1 progress in pharma services with three major contracts secured, but product sales lag due to regulatory and funding headwinds. Revenue guidance for 2024 is lowered, with a strategic pivot to large pharma expected to drive future growth.